Purdue docs use acidity to time cancer drug release; Eternity, PharmaNova partner to develop skin-delivered steroids;

> Researchers at Purdue University have developed nanoparticles that use pH phoresis to improve cancer drug delivery. By focusing on differences in acidity at tumor sites, they were able to control the release therein. Report

> Eternity Healthcare and PharmaNova signed a letter of intent to develop steroids and related drugs for subcutaneous absorption using PharmaNova's NovaSperse nanoparticle technology. Release

> Researchers in China and Chicago have developed a drug-eluting scaffold to deliver chemotherapy to treat pancreatic cancer after surgery. Abstract

> CryoLife's laser fiber-optic delivery system to treat angina snagged FDA premarket approval. The single-use, disposable handset is used with the company's cardiogenesis transmyocardial revascularization system. More

> TWi Pharmaceuticals received U.S. patent allowance for its metformin controlled-release formulation to treat Type 2 diabetes with reduced food effect. Release

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.